Ocular Therapeutix Stock Rises Amid Takeover Speculation

Ocular Therapeutix shares rose 6% amid speculation that a French pharmaceutical company is circling the firm. The speculation was fueled by a "uncooked" alert from Betaville. The company has not commented on the speculation.

Ocular Therapeutix (NASDAQ:OCUL) saw a 6% increase in its stock price today, fueled by speculation that a French pharmaceutical company is considering a takeover. The rumors were sparked by a "uncooked" alert from Betaville, which cited that the potential buyer could offer around $16 per share with a Contingent Value Right (CVR) of $2 per share. This follows an earlier report by Betaville in late June that Ocular Therapeutix had attracted takeover interest [1].

The company was scheduled to speak at the Baird Global Health Conference today, but no official comment has been made regarding the takeover speculation. Ocular Therapeutix has been in the spotlight due to its recent FDA agreement for a registrational trial of Axpaxl and its earnings call in June, where it reported a GAAP EPS of -$0.39, missing estimates by $0.04, but revenue of $13.5M, beating estimates by $0.38M [1].

The potential acquisition could significantly impact Ocular Therapeutix's stock price and market position. Investors should closely monitor the situation and await any official statements from the company or the potential acquirer.

References:
[1] https://seekingalpha.com/news/4492779-ocular-therapeutix-gains-amid-takeover-speculation